NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Brain/CNS Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Glioma

Alliance N0577 - "Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma"

CANCER TYPE: Glioma
RESEARCH BASE: Alliance
NCT NUMBER: NCT00887146
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 08/15/2018 (20:12:39)

Additional Consent Form: VIEW CONSENT FORM 2
UPDATED ON 08/15/2018 (20:12:39)

Additional Consent Form: VIEW CONSENT FORM 3
UPDATED ON 08/15/2018 (20:12:39)

BRIEF DESCRIPTION

Glioma, grade II or III, 1p and 19q co-deletion, IDH mutation, adjuvant, RT + TMZ vs RT + PCV  DCP-001 Eligible






Meningioma

NRG-BN003 - "PHASE III TRIAL OF OBSERVATION VERSUS IRRADIATION FOR A GROSS TOTALLY RESECTED GRADE II MENINGIOMA"

CANCER TYPE: Meningioma
RESEARCH BASE: NRG
NCT NUMBER: NCT03180268
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 09/05/2018 (19:14:32)

BRIEF DESCRIPTION

Meningioma, newly diagnosed, gross totally resected, WHO grade II, observation vs. RT (IMRT or protons).






Mets

RTOG 1119 - "Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer - A Collaborative Study of RTOG and KROG"

CANCER TYPE: Mets
RESEARCH BASE: RTOG 1119
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

METS (progressive parenchymal), from HER2+ breast cancer; Whole Brain RT +/- Lapatinib (Sites must be RPC & CTSU monitored.)






Pituitary

Alliance A071601 - "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas"

CANCER TYPE: Pituitary
RESEARCH BASE: Alliance
NCT NUMBER: NCT03224767
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 08/15/2018 (20:56:54)

BRIEF DESCRIPTION

Papillary craniopharyngioma, BRAF V600E mutation, measurable disease, no prior tx other than surgery, BRAF/MEK inhibitors









  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA